Update on Pharmasset's Hepatitis C Drug Candidates
Pharmasset Reports Interim Study Results For Its Hepatitis C Drugs
Thursday, January 06, 2011
Pharmasset (NASDAQ:VRUS) announced today interim results for the Phase 2b study for its PSI-7977 drug and the Phase 1 study for its PSI-938 drug. Both drugs are designed to treat Hepatitis C.
The Phase 2b study consisted of evaluating the effects of various PSI-7977 dosages in patients with Hepatitis C genotype 1, 2 or 3. The patients also received antiviral drugs commonly used to fight Hepatitis C.
Continue reading this entire article:
Hepatitis C Drug ANA598 Moves to Phase IIb
IP-10 Protein Levels Predict Hepatitis C Treatment Outcome